ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Vasculitis

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Vasculitis

© kubais/Shutterstock.com

Continuing azathioprine and prednisolone past 2 years from diagnosis was superior to withholding them.

The need to find an alternative to prolonged periods of steroid therapy was addressed.

A direct comparison of their clinical characteristics helps distinguish one from another.

(©PavelLPhotoVideo/Shutterstock.com)

Tocilizumab in its subcutaneous form is the first-ever drug designated for giant cell arteritis which affects 230,000 people in the U.S

Blood vessels (©Vlue/Shutterstock.com)

Mayo Clinic’s Dr. Eric Matteson and Dr. Sharon Chung of UCSF provide an update on advances in new treatments for vasculitis.

(©AlilaMedicalMedia/Shutterstock.com)

Two new studies find that abatacept plus prednisone improves duration of remission for giant cell arteritis patients, but not for Takayasu’s arteritis patients.

(Gastrointestinal tract. © Tefi/Shutterstock.com)

Gastrointestinal involvement is known to be associated with primary vasculitis. But in some cases, it may be IBD with secondary vasculitis, this review shows.

Pages

Subscribe to Vasculitis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.